

Financial Services Commission Mauritius

and the second in the state of the first state of the

CIRCULAR LETTER

CL2 - 270617

27 June 2017

To: Insurance Companies structured as PCCs and Professional Reinsurers structured as PCCs

Dear Sir/Madam

New procedures for application for approval of creation of cells

With the aim to streamline the application process for approval of creation of cells under section 7(2) of the Protected Cell Companies Act 1999, and to achieve greater transparency, consistency and efficiency in the approval process, the Financial Services Commission ('Commission') is introducing new procedures as detailed hereunder.

1. Application Form for creation of cell

- 1.1. In order to streamline and standardise applications received at the Commission, all applications for approval of creation of cell will henceforth be required to be submitted as per the Application Form annexed hereto.
- 1.2. The Application Form will enable applicants to provide the comprehensive information required by the Commission for its assessment of the application.
- 1.3. The list of required documents at section 4 of the Application Form should also be duly submitted. Applicants are reminded that the onus is on them to submit complete applications.
- 1.4. Notwithstanding the above, the Commission may call for any additional information and/or documents to be submitted by the applicant as it may deem appropriate.



2. Introduction of processing and annual fees in respect of cells

- 2.1. In order to harmonise and ensure consistency across sectors under the regulatory purview of the Commission, the Financial Services (Consolidated Licensing and Fees) Rules 2008 have been amended to introduce a fee structure for processing and annual fees in relation to companies structured as Protected Cell Companies ('PCCs') and falling under the provisions of the Insurance Act 2005.
- 2.2. The Financial Services (Consolidated Licensing and Fees) (Amendment) Rules 2017, which may be consulted on the website of the Commission (https://www.fscmauritius.org/media/3987/financial-services-consolidated-licensing-and-fees-amendment-rules-2017.pdf), have introduced the following fee structure:

Code	Licence	Processing Fee	Fixed Annual	Variable Annual Fee
		(USD)	Fee	- payable on
			(USD)	quarterly basis (USD)
INS-	Long-Term	USD 2,500 for	USD 3,000 for	(0.35% * Gross
1.1Av	Insurance	the first cell and	the first cell and	Premium from policies
	Business	USD 750 for	USD 600 for	issued)
i	(Protected Cell	every additional	every additional	
	Company)	cell	cell	
INS-	General	USD 2,500 for	USD 3,000 for	(0.35% * Gross
1.2Av	Insurance	the first cell and	the first cell and	Premium)
	Business	USD 750 for	USD 600 for	
	(Protected Cell	every additional	every additional	
	Company)	cell	cell	
INS-	External	USD 1,000 for	USD 1,500 for	Not applicable
1.3Av	Insurance	the first cell and	the first cell and	
	Business	USD 300 for	USD 300 for	
	(Protected Cell	every additional	every additional	
	Company)	cell	cell	
INS-	Professional	USD 1,000 for	USD 1,500 for	Not applicable
1.4Av	Reinsurer	the first cell and	the first cell and	
	(Protected Cell	USD 300 for	USD 300 for	
	Company)	every additional	every additional	
		cell	cell	

2.3. Henceforth, applicants for an insurance business licence intending to be structured as PCCs should apply under the corresponding new licence code as described above.



- 2.4. Upon application for a licence, such applicant will pay the applicable processing fee which will include the creation of the first cell, and after being licensed, the PCC will pay the required processing fee in respect of every additional cell.
- 2.5. In the same vein, PCCs will henceforth pay fixed annual fees (as well as variable annual fees, as applicable) based on their structure and number of cells.
- 2.6. The new fee structure introduced by the Financial Services (Consolidated Licensing and Fees) Rules 2008 will be effective as from 01 July 2017.
- 2.7. Existing insurance companies structured as PCCs and licensed prior to 01 July 2017 must, within 2 months of this Circular Letter, return their current licence to the Commission so that a licence with the appropriate licence code may be issued.

Yours faithfully,

P.K Kuriachen-

Acting Chief Executive

THE FINANCIAL SERVICES COMMISSION

APPLICATION FORM FOR

CREATION OF CELL IN A PROTECTED CELL COMPANY CONDUCTING INSURANCE BUSINESS

(Pursuant to Section 7 of the Protected Cell Companies Act 1999)

NAME OF P	ROTECTED CELL COMPANY (APPLICANT)			
NAME OF	CELL PROPOSED TO BE CREA	TED			
CONTACT P APPLICANT	PERSONS HANDLING APPLICA	TION ON BEHALF OF THE			
	Person 1	Person 2			
Name:					
Position:					
Signature:					
Date:					
	FOR OFFICIAL	IISE			
	Applicants Should Not Write				
Date of Applic	cation 2 0				
Date of Recei	Date of Receipt:				
FSC Code:					

Disclaimer

The Commission will assess each application on its own merits. Incomplete applications are deemed to delay the whole approval process. The Commission may call the applicant and/or the Management Company for meetings where applications may be complex or where business plans are unclear. The Commission will not yield to any pressure from applicants and/or Management Companies to grant approvals unless it is satisfied with the contents of the submissions.

Notes:

- (i) Henceforth, the Commission will require that all applications be accompanied by this Application Form.
- (ii) All incomplete applications received by the Commission will be returned to the Management Company.
- (iii) The applicant is required to immediately inform the Commission of any material change to the information submitted at the time of application.
- (iv) The information/documents required vide this Application Form must not be considered exhaustive. The Commission may require the applicant to provide additional information and documents at any time after the application has been made, in order to enable it to properly process the application.
- (v) Upon inadequate or no response within two (2) months from the date of its last query, the Commission shall not proceed further with the application. After these two months, the Management Company will have to submit a fresh application should the applicant still wish to create the cell.
- (vi) The FSC reserves the right to amend the Application Form to reflect any change in relevant laws, regulations, rules and policy guidelines.
- (vii)Additional sheet(s) may be used, if necessary, to submit the required information.

1. INFORMATION ON THE PROTECTED CELL COMPANY

Licence Number	
Management Company	
Activity	
Group Structure	
Share Capital	
Board of Directors	1. 2. 3. 4. 5. 6. 7.
No of Existing Cells	
List of all Existing Cells and corresponding date of creation	1. 2. 3. 4. 5.

2. CAPITAL STRUCTURE (after proposed creation of cell)

Stated Capital Amount to be represented at no par value				
Types and Classes of Shares (specify whether issued and fully-paid)	Number of Shares	Amount (Rs)		

3. GENERAL DETAILS ON CELL PROPOSED TO BE CREATED ('hereinafter the cell')

l.	The rationale for setting up the cell in the Republic of Mauritius:

2.	Category of insurance business proposed to be-conducted:
3.	Classes of insurance business proposed to be conducted:
4.	Nature of risks to be insured by the cell:
5.	Details of the products of the cell:
6.	Submit all policy documentation and related marketing materials (in the case of reinsurance, submit agreements).
7.	Confirm that the business activity of the cell is not different from the business activity of the Protected Cell Company:
8.	Submit appropriate applications and details on the following (if different from the Protected Cell Company): • Auditors • Actuaries
•	
9.	Submit the cell share agreement
	Attached: Annex
10.	Share Capital Structure of the cell:
11.	Amount paid up and banking details:
	•••••••••••••••••••••••••••••••••••••••

Entity / Person	ıs	Details
Promoters		
Immediate holding co	ompany	
Intermediate sharehol	ders	
Ultimate holding com	ipany	
Ultimate Beneficial C	Owners	
Controlling sharehold	ler*	
Identitying owners	hip arrangements of the cell	, including beneficial owner(s)
 Specifying percenta country of residence Indicatingte whether Attached: Annex	ce of each entity; and er each entity is licensed by	a financial services authority. n a Stock Exchange, please ide
 Specifying percentage country of residence Indicatingte whether Attached: Annex If shares in the cell's un Exchange: 	ce of each entity; and er each entity is licensed by	n a Stock Exchange, please ide
 Specifying percentage country of residence Indicatingte whether Attached: Annex If shares in the cell's un Exchange: 	ce of each entity; and er each entity is licensed by	n a Stock Exchange, please ide
 Specifying percentage country of residence Indicatingte whether Attached: Annex If shares in the cell's un Exchange: 	ce of each entity; and er each entity is licensed by	n a Stock Exchange, please ide
 Specifying percenta country of residence Indicatingte whether Attached: Annex If shares in the cell's understange: Identify shareholders have 	addresses of all natural pers	n a Stock Exchange, please ide
Specifying percents country of residence Indicatingte whether Attached: Annex If shares in the cell's use the	addresses of all natural pers	a Stock Exchange, please ide

Attached (PQ and CDD documents): Annex

17. Is a trust involved or is to be involved in the ownership chain of the cell?
Yes □ No □
If yes, please provide the following details:
 A certified copy of the Trust Deed Profile of beneficiaries Profile of settlor(s) Profile of trustee(s) The relationship between the settlor(s) and the beneficiaries An indication of assets value held by the trust In the case of a discretionary trust: Confirmation that the Commission will be provided with the appropriate CDD documents on beneficiaries as and when distributions are made.
18. Provide details of the proposed method of capitalisation of the cell (whether by way of paid up share capital or otherwise):
10. Provide details of the crisin of the governo of funds to gumment the call.
19. Provide details of the origin of the source of funds to support the cell:
20. Confirmation from the MC that appropriate measures have been taken in accordance with the Code on the Prevention of Money Laundering and Terrorist Financing to establish the source of funds.
Attached: Annex
21. Provide details of any additional financial support of the cell:
22. State whether it is intended that the cell be financially supported by the capital of the core/Protected Cell Company:
23. Confirmation that a proper recourse agreement between the cell and the core is in place:
24. Provide details of alternative plans in the event of losses incurred in the formative years:

	•	g from the Board of the pital and solvency need			provide
	Attached: Annex				
	Provide details of any agreements:	reinsurance/retrocession	on programmes of t	the cell and copies	of draft
27.		the reinsurance/ retroc			
	Full name of reinsurer(s)	Security rati	ng(s)	Attachment	
				1	
				1	
	Provide details and co	pies of the service or m	anagement agreem	ents for the admini	stration
29.	Identify persons who	will conduct the key fu	nctions for the cell	:	
	Key Functions	Name	Position	PO attached]

ŧ

Key Functions	Name	Position	PQ attached
Underwriting			
Claims			
Investment			
MLRO			
Complaints			
Compliance			
Finance			
Risk Management			
Others (please specify)			

	Provide details of the repair the owners of the cell.	porting mechanism put in place b	by the Protected Cell Company to	,
			••••••	
	Supply any other inform ownership or manageme		understanding of the control or	•
			•••••	
	State whether any of the business activity. If yes,		oplication conduct any regulated	
33.	Specify the date on whic	h the cell wishes to commence v	writing insurance business:	
	-		-	
		••••••••••••••	••••••	
	In case the cell will coinsurers, where applicable	_	ease provide details of primary	
	Full name of	Security rating(s)	Commission	
	insurer(s)		structure	
	Please confirm whether consistent in terms of be	- · · · - · ·	d the reinsurance agreements are	
	Please confirm whether consistent in terms of be	nefits, limits of benefits, exclusion	d the reinsurance agreements are	
36.	Please confirm whether consistent in terms of bei whether controls are in p	nefits, limits of benefits, exclusion lace to identify any inconsistence.	d the reinsurance agreements are ons and terms and conditions, and sies in payment of claims.	
36.	Please confirm whether consistent in terms of bei whether controls are in p	nefits, limits of benefits, exclusion lace to identify any inconsistence	d the reinsurance agreements are ons and terms and conditions, and sies in payment of claims.	
36.	Please confirm whether consistent in terms of bei whether controls are in publication. Please provide a list of the and a summary of the service	nefits, limits of benefits, exclusion lace to identify any inconsistence to identify any identification and identifi	d the reinsurance agreements are ons and terms and conditions, and sies in payment of claims. other third party service providers cell;	
36.	Please confirm whether consistent in terms of bei whether controls are in publication. Please provide a list of the and a summary of the service	nefits, limits of benefits, exclusion lace to identify any inconsistence to identify any identification and identifi	d the reinsurance agreements are ons and terms and conditions, and sies in payment of claims. other third party service providers cell;	
36.	Please confirm whether consistent in terms of bei whether controls are in publication. Please provide a list of the and a summary of the service	nefits, limits of benefits, exclusion lace to identify any inconsistence to identify any identification and identifi	d the reinsurance agreements are ons and terms and conditions, and sies in payment of claims. other third party service providers cell;	
36.	Please confirm whether consistent in terms of bei whether controls are in publication. Please provide a list of the and a summary of the service	nefits, limits of benefits, exclusion lace to identify any inconsistence to identify any identification and identification are identification and identification and identification and identification and identification and identification are identification and identifi	d the reinsurance agreements are ons and terms and conditions, and sies in payment of claims. other third party service providers cell;	

3	7. Please provide details of any common own any of the third party service providers liste	-	other con	nection betwe	en the cell and
	8. Confirmation from the Board of the Protect and of the policyholders and potential polifinancial centre will not be jeopardised by the Documents to be submitted for each Contraction.	icyholders the creation	and the	reputation of cell.	Mauritius as
	Documents Documents	Subm	nitted	Comments	Document reference
1.	Application Form for creation of cell in a	Yes 🗆	No □		reterence
2.	Protected Cell Company Resolution of the Board of Directors of the Protected Cell Company for the creation of the cell	Yes 🗆	No 🗆		
3.	 Business plan including but not restricted to the following: Sources of business Target markets Products Organisation, management, controls and business risk acceptance Operational/procedure manuals Distribution network All intermediaries through which the cell will market its products, including the country of operation of the intermediaries 	Yes 🗆	No □		
4.	 3 year financial projections including but not restricted to the following: Balance Sheet Profit and Loss Statement Solvency Calculations Assumptions used 	Yes 🗆	No 🗆		
5.	Actuarial report on the feasibility of the	Yes 🗆	No 🗆		
6.	 business plan and financial projections Actuarial certification that: the products of the cell are insurance products (where applicable); reinsurance/retrocession arrangements are adequate; and proposed premium is adequate. 	Yes 🗆	No □		
7.	Draft insurance policy showing terms and conditions and benefits	Yes 🗆	No 🗆		

	Documents	Submitted		Comments	Document
					reference
8.	Marketing materials in respect of the products of the cell (in case of reinsurance, marketing materials for the underlying products should be submitted)	Yes □	No 🗆		
9.	Appropriate applications in relation to auditors and actuaries (if different from the Protected Cell Company)	Yes 🗆	No 🗆		
10.	Cell share agreement	Yes 🗆	No □		
11.	Recourse agreement between the cell and the core / Protected Cell Company	Yes 🗆	No □		
12.	Draft reinsurance/retrocession agreements (if any)	Yes 🗆	No 🗆		
13.	Copy of the service or management agreements for the administration of the cell	Yes □	No 🗆		
14.	 Identifying ownership arrangements of the cell, including beneficial owner(s); Specifying percentage of all holdings; Stating country of residence of each entity; and Indicating whether each entity is licensed by a financial services authority. 	Yes 🗆	No 🗆		
15.	Evidence of proceeds of cell share capital	Yes □	No 🗆		
16.	Certified true copy of documentation on the: Promoters Immediate holding company Intermediate holding company/companies Ultimate holding company Ultimate beneficial owner(s) Controllers	Yes 🗆	No □		
	 (i) For individuals: PQ Form CV Proof of address ID/passport copy (ii) For corporate bodies: Certificate of incorporation Memorandum and articles of association Register of directors (documents to be submitted as per (i) above) 				

	Documents	Submitted	Comments	Document reference
	 Register of shareholders (in case of listed company, shareholders holding more than 5%) Audited Financial Statements for last 3 years (where applicable) 			
	 (iii) For trusts: Name of the trust and its date and place of registration Trust deed An indication of the asset value 			
	 held by the trust Identity of settlor, trustee(s) and beneficiaries (documents to be submitted accordingly as per (i) above) 			
	Indication of whether any acquirer or its associates directly or indirectly owns or holds shares or any legal or beneficial interest in any insurance company or its associates or in any insurance broking company or its associates - For each acquirer or its associates, indicate any positions currently held officer or employee - in any insurance company or its associates or in any insurance broking company or its associates. - For each insurer or insurance broking company, indicate the percentage of ownership or shares/any legal or beneficial interest.	Yes No D		
18.	Statement on why the acquirer is of the opinion that the application, if approved, will be in the public interest, in the interest of the policyholders and of the insurer.	Yes □ No □		
	Letter signed by two directors of the Protected Cell Company certifying that the creation of the cell will not adversely affect the financial position and solvency of the Protected Cell Company	Yes □ No □		
20.	Undertaking from the Board of the Protected Cell Company that it will provide capital for ongoing capital and solvency needs of the cell, should the need arise.	Yes No No		

	Documents	Submitted		Comments	Document reference
21.	Certificate of good standing on any entity involved in regulated financial services activities (where applicable)	Yes 🗆	No 🗆		
22.	Confirmation (i) that the MC has made all reasonable enquiries and has conducted all due diligence checks that it considered appropriate on the cell shareholder up to the UBO and any person who effectively directs the business, and (ii) that to the best of its knowledge, they have not been convicted of any offence or involved in any fraudulent matters	Yes □	No □		
23.	Confirmation from the MC that appropriate measures have been taken in accordance with the Code on the Prevention of Money Laundering and Terrorist Financing to establish the source of funds	Yes 🗆	No □		•

DECLARATION BY APPLICANT/APPLICANT'S REPRESENTATIVE

I certify that the information furnished in this application and additional submission, as required in Annex hereto, is complete and correct to the best of my knowledge and belief.
I also undertake to notify the Financial Services Commission of any material change in information/documents submitted with respect to the above.
Name of Applicant/Applicant's Representative (BLOCK CAPITALS)
Signature of Applicant/Applicant's Representative:
••••••
Date: